



Serial No.: 10/748,117

## CLAIMS:


1. (Currently amended) An immunogenic composition comprising: (a) water; (b) a polymer microparticle comprising a polymer selected from a poly( $\alpha$ -hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and a polycyanoacrylate; (c) an antigen adsorbed to the microparticle; and (d) a synthetic phospholipid compound comprising: (i) one or more phosphoryl groups independently selected from a



2. (Withdrawn, Original) The immunogenic composition of claim 1, wherein the



3. (Original) The immunogenic composition of claim 1, wherein the phospholipid



Serial No.: 10/748,117

4. (Original) The immunogenic composition of claim 1, wherein the phospholipid


compound comprises four to eight of said  $\left[ \text{CH}_2 \right]_n \text{CH}_3$  groups.

5. (Original) The immunogenic composition of claim 1, wherein the phospholipid

compound comprises six of said  $\left[ \text{CH}_2 \right]_n \text{CH}_3$  groups.

6. (Original) The immunogenic composition of claim 1, wherein the phospholipid compound does not comprise a saccharide group.

7. (Original) The immunogenic composition of claim 1, wherein the phospholipid compound is a compound having the following formula:



wherein:

Serial No.: 10/748,117

R<sup>1</sup> is selected from the group consisting of

- (a) C(O);
- (b) C(O)—C<sub>1-14</sub> alkyl-C(O), wherein the C<sub>1-14</sub> alkyl is optionally substituted with hydroxy, C<sub>1-5</sub> alkoxy, C<sub>1-5</sub> alkyleneedioxy, C<sub>1-5</sub> alkylamino, or C<sub>1-5</sub>-alkyl-aryl, wherein the aryl moiety of the C<sub>1-5</sub>-alkyl-aryl is optionally substituted with C<sub>1-5</sub> alkoxy, C<sub>1-5</sub> alkylamino, C<sub>1-5</sub> alkoxy-amino, C<sub>1-5</sub> alkylamino-C<sub>1-5</sub> alkoxy, —O—C<sub>1-5</sub> alkylamino-C<sub>1-5</sub> alkoxy, —O—C<sub>1-5</sub> alkylamino-C(O)—C<sub>1-5</sub> alkyl C(O)OH, —O—C<sub>1-5</sub> alkylamino-C(O)—C<sub>1-5</sub> alkyl-C(O)—C<sub>1-5</sub> alkyl;
- (c) C<sub>2</sub> to C<sub>15</sub> straight or branched chain alkyl optionally substituted with hydroxy or alkoxy; and
- (d) —C(O)—C<sub>6-12</sub> arylene-C(O)— wherein the arylene is optionally substituted with hydroxy, halogen, nitro or amino;

a and b are independently 0, 1, 2, 3 or 4;

d, d', d'', e, e' and e'' are independently an integer from 1 to 4;

X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup> and Y<sup>2</sup> are independently selected from the group consisting of a null, oxygen, NH and N(C(O)C<sub>1-4</sub> alkyl), and N(C<sub>1-4</sub> alkyl)<sub>2</sub> ;


W<sup>1</sup> and W<sup>2</sup> are independently selected from the group consisting of carbonyl, methylene, sulfone and sulfoxide;

R<sup>2</sup> and R<sup>5</sup> are independently selected from the group consisting of:

- (a) C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkyl which is optionally substituted with oxo, hydroxy or alkoxy,
- (b) C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkenyl or dialkenyl which is optionally substituted with oxo, hydroxy or alkoxy;
- (c) C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkoxy which is optionally substituted with oxo, hydroxy or alkoxy;
- (d) —NH—C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkyl, wherein the alkyl group is

Serial No.: 10/748,117

optionally substituted with oxo, hydroxy or alkoxy; and



wherein Z is selected from the group consisting of O and NH, and M and N are independently selected from the group consisting of C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkyl, alkenyl, alkoxy, acyloxy, alkylamino, and acylamino;

R<sup>3</sup> and R<sup>6</sup> are independently selected from the group consisting of C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkyl or alkenyl, optionally substituted with fluoro or oxo;

R<sup>4</sup> and R<sup>7</sup> are independently selected from the group consisting of C(O)C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkyl or alkenyl; C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkoxy; C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkenyl; wherein the alkyl, alkenyl or alkoxy groups are independently and optionally substituted with hydroxy, fluoro or C<sub>1</sub> to C<sub>5</sub> alkoxy;

G<sup>1</sup>, G<sup>2</sup>, G<sup>3</sup> and G<sup>4</sup> are independently selected from the group consisting of oxygen, methylene, amino, thiol, —NHC(O)—, and —N(C(O)C<sub>1-4</sub> alkyl)—; or G<sup>2</sup> R<sup>4</sup> or G<sup>4</sup> R<sup>7</sup> may together be a hydrogen atom or hydroxyl;

or a pharmaceutically acceptable salt thereof.

8. (Original) The immunogenic composition of claim 7, wherein R<sup>1</sup> is C(O); a, b, d, d', d'', e, e' and e'' are independently 1 or 2; X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup> and Y<sup>2</sup> are NH; W<sup>1</sup> and W<sup>2</sup> are carbonyl; R<sup>2</sup> and R<sup>5</sup> are C<sub>10</sub> to C<sub>20</sub> straight chain alkyl which is substituted with oxo; R<sup>3</sup> and R<sup>6</sup> are C<sub>5</sub>-C<sub>10</sub> straight chain alkyl; R<sup>4</sup> and R<sup>7</sup> are C(O)C<sub>8</sub>-C<sub>14</sub> straight chain alkyl or alkenyl; and G<sup>1</sup>, G<sup>2</sup>, G<sup>3</sup> and G<sup>4</sup> are oxygen.

9. (Original) The immunogenic composition of claim 7, wherein R<sup>1</sup> is C(O); a and b are 2; d, d', e and e' are 1; d'' and e'' are 2; X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup> and Y<sup>2</sup> are NH; W<sup>1</sup> and W<sup>2</sup> are carbonyl; R<sup>2</sup> and R<sup>5</sup> are C<sub>13</sub> straight chain alkyl which is substituted with oxo at the 2 position; R<sup>3</sup> and R<sup>6</sup> are C<sub>7</sub> straight chain alkyl; R<sup>4</sup> and R<sup>7</sup> are C(O)C<sub>11</sub> straight chain alkyl; G<sup>1</sup>, G<sup>2</sup>, G<sup>3</sup> and G<sup>4</sup> are oxygen.

Serial No.: 10/748,117

10. (Previously presented) The immunogenic composition of claim 1, wherein the phospholipid is entrapped within the microparticles.
11. (Previously presented) The immunogenic composition of claim 1, wherein the phospholipid is adsorbed to the microparticles.
12. (Previously presented) The immunogenic composition of claim 1, wherein the phospholipid is dispersed in aqueous solution.
13. (Previously presented) The immunogenic composition of claim 1, wherein two or more antigens are adsorbed to the microparticles.
14. (Previously presented) The immunogenic composition of claim 1, wherein additional antigen is entrapped within the microparticles.
15. (Previously presented) The immunogenic composition of claim 1, wherein the antigen is a polypeptide-containing antigen.
16. (Previously presented) The immunogenic composition of claim 1, wherein the antigen is a polynucleotide-containing antigen.
17. (Withdrawn, Previously presented) The immunogenic composition of claim 1, wherein the antigen is derived from a tumor cell.
18. (Previously presented) The immunogenic composition of claim 1, wherein the antigen is derived from a pathogenic organism.
19. (Original) The immunogenic composition of claim 18, wherein the pathogenic organism is selected from a virus, a bacterium, a fungus and a parasite.

Serial No.: 10/748,117

20. (Original) The immunogenic composition of claim 18, wherein the pathogenic organism is selected from HIV, hepatitis B virus, hepatitis C virus, meningitis B, *Haemophilus influenza* type B, pertussis, diphtheria, tetanus, and influenza A virus.

21. (Original) The immunogenic composition of claim 18, wherein the pathogenic organism is selected from human immunodeficiency virus, *Neisseria meningitidis*, and hepatitis virus.

22. (Previously presented) The immunogenic composition of claim 1, wherein the immunogenic composition further comprises a surfactant.

23. (Previously presented) The immunogenic composition of claim 1, wherein the microparticles have a diameter between 500 nanometers and 20 microns.

24. (Previously presented) The immunogenic composition of Claim 1, wherein the poly( $\alpha$ -hydroxy acid) is selected from poly(L-lactide), poly(D,L-lactide) and poly(lactide-co-glycolide).

25. (Previously presented) The immunogenic composition of claim 1, wherein the poly( $\alpha$ -hydroxy acid) is poly(D,L-lactide-co-glycolide).

26. (Original) The immunogenic composition of claim 25, wherein the poly(D,L-lactide-co-glycolide) has a lactide:glycolide molar ratio ranging from 40:60 to 60:40.

27. (Previously presented) The immunogenic composition of claim 1, further comprising a supplemental immunological adjuvant.

28. (Previously presented) The immunogenic composition of claim 1, wherein the immunogenic composition is an injectable composition.

Serial No.: 10/748,117

29. (Withdrawn, Previously presented) A method of delivering a therapeutic amount of an antigen to a vertebrate host animal, comprising administering to the host animal the immunogenic composition of claim 1.

30. (Withdrawn, Previously presented) A method of treating a host animal having a pathogenic organism infection or tumor comprising administering to the animal the immunogenic composition of claim 1.

31. (Withdrawn, Previously presented) A method of immunizing a host animal against a tumor or infection by a pathogenic organism comprising administering to the animal the immunogenic composition of claim 1.

32. (Withdrawn, Previously presented) A method of stimulating an immune response in a host animal, comprising administering to the host animal the immunogenic composition of claim 1.

33. (Withdrawn, Original) The method of claim 32, wherein the immune response comprises a humoral immune response.

34. (Withdrawn, Original) The method of claim 32, wherein the immune response comprises a cellular immune response.

35. (Withdrawn, Original) The method of claim 32, wherein the immune response is raised against a viral, bacterial, or parasitic infection.

36. (Withdrawn, Original) The method of claim 32, wherein the immune response is raised against a tumor.


37. (Withdrawn, Original) The method of claim 32, wherein the host animal is a vertebrate animal.

Serial No.: 10/748,117.

38. (Withdrawn, Original) The method of claim 32, wherein the host animal is a mammal.

39. (Withdrawn, Original) The method of claim 32, wherein the host animal is a human.

40. (Withdrawn, Original) An immunogenic composition comprising: (a) water; (b) a metabolizable oil; (c) an emulsifying agent; (d) an antigen; and (e) a phospholipid compound comprising: (i) one or more phosphoryl groups independently selected from a




$\left[CH_2\right]_nCH_3$ , in which n is independently an integer ranging from 6 to 20,

wherein the composition is an oil-in-water emulsion having oil and aqueous phases, and wherein the oil phase is in the form of oil droplets substantially all of which are less than 1 micron in diameter.

41. (Withdrawn, Original) The immunogenic composition of claim 40, wherein the


phospholipid compound comprises one or more

groups and no




Serial No.: 10/748,117

42. (Withdrawn, Original) The immunogenic composition of claim 40, wherein the



phospholipid compound comprises one or more groups and no



43. (Withdrawn, Original) The immunogenic composition of claim 40, wherein the

phospholipid compound comprises four to eight of said  $\left[ \text{CH}_2 \right]_n \text{CH}_3$  groups.


44. (Withdrawn, Original) The immunogenic composition of claim 40, wherein the

phospholipid compound comprises six of said  $\left[ \text{CH}_2 \right]_n \text{CH}_3$  groups.

45. (Withdrawn, Original) The immunogenic composition of claim 40, wherein the phospholipid compound does not comprise a saccharide group.

46. (Withdrawn, Original) The immunogenic composition of claim 40, wherein the phospholipid compound is a compound having the following formula:

Serial No.: 10/748,117



wherein:

 $R^1$  is selected from the group consisting of

- (a)  $C(O)$ ;
- (b)  $C(O)-C_{1-14}$  alkyl- $C(O)$ , wherein the  $C_{1-14}$  alkyl is optionally substituted with hydroxy,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkyleneedioxy,  $C_{1-5}$  alkylamino, or  $C_{1-5}$ -alkyl-aryl, wherein the aryl moiety of the  $C_{1-5}$ -alkyl-aryl is optionally substituted with  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkylamino,  $C_{1-5}$  alkoxy-amino,  $C_{1-5}$  alkylamino- $C_{1-5}$  alkoxy,  $-O-C_{1-5}$  alkylamino- $C_{1-5}$  alkoxy,  $-O-C_{1-5}$  alkylamino- $C(O)-C_{1-5}$  alkyl,  $C(O)OH$ ,  $-O-C_{1-5}$  alkylamino- $C(O)-C_{1-5}$  alkyl- $C(O)-C_{1-5}$  alkyl;
- (c)  $C_2$  to  $C_{15}$  straight or branched chain alkyl optionally substituted with hydroxy or alkoxy; and
- (d)  $-C(O)-C_{6-12}$  arylene- $C(O)-$  wherein the arylene is optionally substituted with hydroxy, halogen, nitro or amino;

 $a$  and  $b$  are independently 0, 1, 2, 3 or 4;

Serial No.: 10/748,117


d, d', d'', e, e' and e'' are independently an integer from 1 to 4;

X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup> and Y<sup>2</sup> are independently selected from the group consisting of a null, oxygen, NH and N(C(O)C<sub>1-4</sub> alkyl), and N(C<sub>1-4</sub> alkyl)<sub>2</sub>;

W<sup>1</sup> and W<sup>2</sup> are independently selected from the group consisting of carbonyl, methylene, sulfone and sulfoxide;

R<sup>2</sup> and R<sup>5</sup> are independently selected from the group consisting of:

- (a) C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkyl which is optionally substituted with oxo, hydroxy or alkoxy;
- (b) C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkenyl or dialkenyl which is optionally substituted with oxo, hydroxy or alkoxy;
- (c) C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkoxy which is optionally substituted with oxo, hydroxy or alkoxy;
- (d) —NH—C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkyl, wherein the alkyl group is optionally substituted with oxo, hydroxy or alkoxy; and



wherein Z is selected from the group consisting of O and NH, and M and N are independently selected from the group consisting of C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkyl, alkenyl, alkoxy, acyloxy, alkylamino, and acylamino;

R<sup>3</sup> and R<sup>6</sup> are independently selected from the group consisting of C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkyl or alkenyl, optionally substituted with fluoro or oxo;

R<sup>4</sup> and R<sup>7</sup> are independently selected from the group consisting of C(O)C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkyl or alkenyl; C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkyl; C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkoxy; C<sub>2</sub> to C<sub>20</sub> straight chain or branched chain alkenyl; wherein the alkyl, alkenyl or alkoxy groups are independently and optionally substituted with hydroxy, fluoro or C<sub>1</sub> to C<sub>5</sub> alkoxy;

Serial No.: 10/748,117

G<sup>1</sup>, G<sup>2</sup>, G<sup>3</sup> and G<sup>4</sup> are independently selected from the group consisting of oxygen, methylene, amino, thiol, —NHC(O)—, and —N(C(O)C<sub>1-4</sub> alkyl)—; or G<sup>2</sup> R<sup>4</sup> or G<sup>4</sup> R<sup>7</sup> may together be a hydrogen atom or hydroxyl;  
or a pharmaceutically acceptable salt thereof. (Original)

47. (Withdrawn, Original) The immunogenic composition of claim 46, wherein R<sup>1</sup> is C(O); a, b, d, d', d'', e, e' and e'' are independently 1 or 2; X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup> and Y<sup>2</sup> are NH; W<sup>1</sup> and W<sup>2</sup> are carbonyl; R<sup>2</sup> and R<sup>5</sup> are C<sub>10</sub> to C<sub>20</sub> straight chain alkyl which is substituted with oxo; R<sup>3</sup> and R<sup>6</sup> are C<sub>5</sub>-C<sub>10</sub> straight chain alkyl; R<sup>4</sup> and R<sup>7</sup> are C(O)C<sub>8</sub>-C<sub>14</sub> straight chain alkyl or alkenyl; and G<sup>1</sup>, G<sup>2</sup>, G<sup>3</sup> and G<sup>4</sup> are oxygen.

48. (Withdrawn, Original) The immunogenic composition of claim 46, wherein R<sup>1</sup> is C(O); a and b are 2; d, d', e and e' are 1; d'' and e'' are 2; X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup> and Y<sup>2</sup> are NH; W<sup>1</sup> and W<sup>2</sup> are carbonyl; R<sup>2</sup> and R<sup>5</sup> are C<sub>13</sub> straight chain alkyl which is substituted with oxo at the 2 position; R<sup>3</sup> and R<sup>6</sup> are C<sub>7</sub> straight chain alkyl; R<sup>4</sup> and R<sup>7</sup> are C(O)C<sub>11</sub> straight chain alkyl; G<sup>1</sup>, G<sup>2</sup>, G<sup>3</sup> and G<sup>4</sup> are oxygen.

49. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein substantially all of the oil droplets are less than 500 nm in diameter.

50. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein substantially all of the oil droplets are less than 250 nm in diameter.

51. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the metabolizable oil is selected from an animal oil and a vegetable oil.

52. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the metabolizable oil is a fish oil.

Serial No.: 10/748,117

53. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the metabolizable oil is a branched, polyunsaturated hydrocarbon having from 20-40 carbon atoms.

54. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the metabolizable oil is a terpenoid.

55. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the metabolizable oil is squalene.

56. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the emulsifying agent comprises a sorbitan derivative.

57. (Withdrawn, Original) The immunogenic composition of claim 56, wherein the sorbitan derivative is selected sorbitan fatty acid monoesters, sorbitan fatty acid sesquiesters, sorbitan fatty acid triesters, polyoxyethylene sorbitan fatty acid monoesters and polyoxyethylene sorbitan fatty acid triesters.

58. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the composition comprises a plurality of emulsifying agents.

59. (Withdrawn, Original) The immunogenic composition of claim 58, wherein the composition comprises a sorbitan ester and a polyoxyethylene sorbitan ester.

60. (Withdrawn, Original) The immunogenic composition of claim 59, wherein the composition comprises polyoxyethylene sorbitan monooleate and sorbitan trioleate.

61. (Withdrawn, Original) The immunogenic composition of claim 58, wherein the composition comprises a first emulsifying agent having an HLB value ranging from 1 to 9 and a second emulsifying agent having an HLB value ranging from 10 to 20.

Serial No.: 10/748,117

62. (Withdrawn, Original) The immunogenic composition of claim 58, wherein the composition comprises a first emulsifying agent having an HLB value ranging from 1 to 4 and a second emulsifying agent having an HLB value ranging from 12 to 17.

63. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the phospholipid is dissolved or dispersed in the oil phase.

64. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the phospholipid is dispersed in the aqueous phase.

65. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the antigen is dissolved or dispersed in the aqueous phase.

66. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the antigen is a polypeptide-containing antigen.

67. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the antigen is a polynucleotide-containing antigen.

68. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the antigen is derived from a tumor cell.

69. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the antigen is derived from a pathogenic organism.

70. (Withdrawn, Original) The immunogenic composition of claim 69, wherein the pathogenic organism is selected from a virus, a bacterium, a fungus and a parasite.

71. (Withdrawn, Original) The immunogenic composition of claim 69, wherein the pathogenic organism is selected from HIV, hepatitis B virus, hepatitis C virus, meningitis B, *Haemophilus influenza* type B, pertussis, diphtheria, tetanus, and influenza A virus.

Serial No.: 10/748,117

72. (Withdrawn, Original) The immunogenic composition of claim 69, wherein the pathogenic organism is selected from human immunodeficiency virus, *Neisseria meningitidis*, and hepatitis virus.

73. (Withdrawn, Previously presented) The immunogenic composition of claim 40, further comprising a supplemental immunological adjuvant.

74. (Withdrawn, Previously presented) The immunogenic composition of claim 40, wherein the immunogenic composition is an injectable composition.

75. (Withdrawn, Previously presented) A method of delivering a therapeutic amount of an antigen to a vertebrate host animal, comprising administering to the host animal the immunogenic composition of claim 40.

76. (Withdrawn, Previously presented) A method of treating a host animal having a pathogenic organism infection or tumor comprising administering to the animal the immunogenic composition of claim 40.

77. (Withdrawn, Previously presented) A method of immunizing a host animal against a tumor or infection by a pathogenic organism comprising administering to the animal the immunogenic composition of claim 40.

78. (Withdrawn, Previously presented) A method of stimulating an immune response in a host animal, comprising administering to the host animal the immunogenic composition of claim 40.

79. (Withdrawn, Original) The method of claim 78, wherein the immune response comprises a humoral immune response.

Serial No.: 10/748,117

80. (Withdrawn, Original) The method of claim 78, wherein the immune response comprises a cellular immune response.

81. (Withdrawn, Original) The method of claim 78, wherein the immune response is raised against a viral, bacterial, or parasitic infection.

82. (Withdrawn, Original) The method of claim 78, wherein the immune response is raised against a tumor.

83. (Withdrawn, Original) The method of claim 78, wherein the host animal is a vertebrate animal.

84. (Withdrawn, Original) The method of claim 78, wherein the host animal is a mammal.

85. (Withdrawn, Original) The method of claim 78, wherein the host animal is a human.